QUIDELORTHO CORP (QDEL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-28..
Quick ratio
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 993.40M USD | Liabilities, Current |
| Cash and equivalents | 123.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 352.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 618.90M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | $993.40M | $123.40M | (m) | $352.00M | $618.90M | (m) |
| 2026-03-29 | (m) | $962.40M | $140.40M | (m) | $359.90M | $611.50M | (m) |
| 2025-12-28 | (m) | $966.10M | $169.80M | (m) | $417.00M | $577.60M | (m) |
| 2025-09-28 | (m) | $767.90M | $98.10M | (m) | $386.50M | $613.80M | (m) |
| 2025-06-29 | (m) | $1.14B | $151.70M | (m) | $275.00M | $578.70M | (m) |
| 2025-03-30 | (m) | $1.05B | $127.10M | (m) | $286.00M | $563.20M | (m) |
| 2024-12-29 | $380.70M | $998.80M | $98.30M | $0.00 | $282.40M | $533.70M | 0.38× |
| 2024-09-29 | $438.60M | $1.03B | $143.70M | $0.00 | $294.90M | $577.00M | 0.43× |
| 2024-06-30 | $376.50M | $932.40M | $107.00M | $0.00 | $269.50M | $602.00M | 0.40× |
| 2024-03-31 | $350.20M | $779.80M | $78.50M | $0.00 | $271.70M | $583.10M | 0.45× |
| 2023-12-31 | $470.60M | $833.80M | $118.90M | $48.40M | $303.30M | $577.80M | 0.56× |
| 2023-10-01 | $524.40M | $860.00M | $149.30M | $43.90M | $331.20M | $551.70M | 0.61× |
| 2023-07-02 | $470.40M | $790.00M | $178.60M | $45.10M | $246.70M | $542.20M | 0.60× |
| 2023-04-02 | $671.50M | $907.80M | $353.90M | $42.80M | $274.80M | $528.60M | 0.74× |
| 2023-01-01 | $798.90M | $1.01B | $292.90M | $52.10M | $453.90M | $524.10M | 0.79× |
| 2022-10-02 | $680.60M | $872.70M | $212.20M | $51.80M | $416.60M | $536.20M | 0.78× |
| 2022-07-03 | $810.70M | $900.00M | $379.00M | $52.50M | $379.20M | $552.70M | 0.90× |
| 2022-01-02 | $1.21B | $323.50M | $802.80M | $25.70M | $378.00M | $198.80M | 3.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |